Quick Facts

• The global NAD+ market reached $577 million in 2025 and is projected to hit $1.5 billion by 2032
• Research shows NAD+ infusions are “very inefficient” at increasing cellular levels compared to precursor supplements
• Clinical trials focus mainly on neurodegenerative diseases, not general anti-aging claims

The wellness industry’s enthusiasm for NAD+ supplements and infusions has created a boom worth hundreds of millions of dollars. But scientists studying this cellular compound say the marketing claims have raced ahead of the research.

Christopher Martens, director of the Delaware Center for Cognitive Aging Research, initially found the attention “exciting.” Now he warns that “the cart may be well ahead of the horse.”

NAD+ (nicotinamide adenine dinucleotide) plays a crucial role in cellular energy production. Studies show NAD+ levels decline with age, which has sparked interest in supplements that might restore these levels.

The market reflects this enthusiasm. The global NAD+ enhancer market grew to $577 million in 2025 and is expected to reach $1.5 billion by 2032, representing a 15.2% annual growth rate.

But research reveals significant gaps between promises and proof. Preliminary findings from one pilot study suggest NAD+ infusions are “very inefficient” at increasing cellular levels. The molecule has “no easy door” to enter cells from the bloodstream, according to researcher Pojednic.

IV infusions also come with unpleasant side effects. Studies report “moderate to severe abdominal cramping, diarrhea, nausea, vomiting” in participants receiving NAD+ infusions.

More promising results come from precursor supplements. A 2026 study of Qualia NAD+ showed participants had a 67% increase in NAD+ levels compared to just 4% in the placebo group. Swiss researchers found that NR and NMN precursors increased circulating NAD+ levels by about two-fold after 14 days.

Safety appears good at studied doses. Research shows NAD+ supplementation has “very limited side effects” at doses up to 3 grams daily. However, most clinical trials focus on specific medical conditions like Alzheimer’s disease and Parkinson’s disease, not general anti-aging.

Klein, another researcher in the field, says he’s “not convinced these supplements have been studied adequately enough in humans to show the benefits outweigh any harm.” This caution contrasts sharply with marketing materials that promise enhanced energy and longevity.

The cost raises additional questions. Treatments can cost “hundreds or thousands of dollars,” yet rigorous randomized controlled trials supporting anti-aging claims don’t exist as of 2026.

Current research concentrates on neurodegenerative disorders and metabolic conditions like type 2 diabetes. Larger, longer-term trials with clear clinical endpoints are needed before making broader health claims.

The industry is responding to scrutiny by moving toward pharmaceutical-grade manufacturing and third-party testing. Companies providing transparent clinical data will likely dominate premium market segments.

For now, the biological rationale for NAD+ supplementation remains compelling. Research consistently shows NAD+ levels decline with age across multiple species. The challenge lies in translating this basic science into proven human benefits.

Scientists emphasize that more rigorous research is essential before the wellness industry’s enthusiasm can be justified by solid evidence.

Read more: Marketers say NAD+ pills and infusions can boost longevity. What’s the evidence?